TLX.AX ASX
Telix Pharmaceuticals Limited
1W: -4.7%
1M: -6.8%
3M: -10.2%
YTD: +50.7%
1Y: +10.1%
3Y: +29.6%
5Y: +130.8%
A$15.18 ($10.55)
-0.43 (-2.75%)
Weekly Expected Move ±10.3%
A$12
A$14
A$15
A$17
A$18
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$27M
-162.3% ▼
Capital Expenditures
$59M
-72.8% ▼
5Y CAGR: +183.3%
Free Cash Flow
-$86M
-1051.7% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$498M
-184.8% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$81M | -$104M | $5M | $0 | -$11M |
| Depreciation & Amort. | $5M | $5M | $7M | $0 | $34M |
| Stock-Based Comp. | $1M | $8M | $9M | $0 | $0 |
| Change in Working Capital | -$3M | -$1M | -$58M | -$64M | -$70M |
| Other Non-Cash Items | $32M | $41M | $60M | $107M | $21M |
| Operating Cash Flow | -$59M | -$64M | $24M | $43M | -$27M |
| — Investing Activities — | |||||
| Capital Expenditures | -$1M | -$14M | -$10M | -$14M | -$87M |
| Acquisitions (Net) | $0 | -$973K | -$1M | -$35M | -$342M |
| Investment Purchases | $0 | $0 | -$13M | -$52M | -$1M |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | -$1M | -$2M | -$1M | -$34M | -$13M |
| Investing Cash Flow | -$3M | -$17M | -$25M | -$135M | -$443M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$340K | $3M | $6M | $653M | -$450K |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$596K | -$1M | -$2M | -$15M | -$8M |
| Financing Cash Flow | $3M | $175M | $10M | $639M | -$6M |
| Net Change in Cash | -$56M | $94M | $7M | $587M | -$498M |
| Cash End of Period | $22M | $116M | $123M | $710M | $213M |
| Free Cash Flow | -$61M | -$78M | $13M | $9M | -$86M |